LU92782I2 - Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson - Google Patents

Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson Download PDF

Info

Publication number
LU92782I2
LU92782I2 LU92782C LU92782C LU92782I2 LU 92782 I2 LU92782 I2 LU 92782I2 LU 92782 C LU92782 C LU 92782C LU 92782 C LU92782 C LU 92782C LU 92782 I2 LU92782 I2 LU 92782I2
Authority
LU
Luxembourg
Prior art keywords
safinamide
levodopa
pdi
parkinson
drugs
Prior art date
Application number
LU92782C
Other languages
English (en)
French (fr)
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92782(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of LU92782I2 publication Critical patent/LU92782I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92782C 2003-04-11 2015-07-22 Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson LU92782I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11

Publications (1)

Publication Number Publication Date
LU92782I2 true LU92782I2 (fr) 2015-09-22

Family

ID=33159845

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92782C LU92782I2 (fr) 2003-04-11 2015-07-22 Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson

Country Status (28)

Country Link
US (3) US8283380B2 (el)
EP (2) EP1613296B1 (el)
JP (2) JP2006522800A (el)
KR (2) KR20110070929A (el)
CN (2) CN1771030A (el)
AR (1) AR044007A1 (el)
AT (1) ATE435012T1 (el)
AU (1) AU2004228782B2 (el)
BR (1) BRPI0409364A (el)
CA (1) CA2523188C (el)
CY (3) CY1109295T1 (el)
DE (1) DE602004021790D1 (el)
DK (2) DK1613296T3 (el)
ES (2) ES2454272T3 (el)
FR (1) FR15C0054I2 (el)
HU (1) HUS1500043I1 (el)
IL (2) IL171331A (el)
LU (1) LU92782I2 (el)
MX (1) MXPA05010873A (el)
NL (1) NL300752I2 (el)
NO (3) NO334316B1 (el)
NZ (1) NZ542910A (el)
PL (2) PL1613296T3 (el)
PT (2) PT1613296E (el)
RU (1) RU2342929C2 (el)
SI (2) SI1613296T1 (el)
TW (1) TWI340640B (el)
WO (1) WO2004089353A2 (el)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
JP4350508B2 (ja) * 2001-09-03 2009-10-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ガバペンチンまたはその類似体とα−アミノアミドとを含む薬剤組成物およびその鎮痛用途
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
KR101233711B1 (ko) * 2003-08-25 2013-02-18 뉴론 파마슈티칼즈 에스. 피. 에이. 항염증제로서 유용한 알파-아미노아미드 유도체
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
NZ553970A (en) * 2004-09-10 2010-01-29 Newron Pharm Spa Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
EP1954256A2 (en) 2005-11-09 2008-08-13 Torrent Pharmaceuticals Ltd Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
KR101380137B1 (ko) * 2005-12-22 2014-04-11 뉴론 파마슈티칼즈 에스. 피. 에이. 칼슘 및/또는 나트륨 채널 조절제로서 2-페닐에틸아미노유도체
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
PL2474521T3 (pl) 2006-06-19 2017-01-31 Newron Pharmaceuticals S.P.A. 2-[4-(3- i 2-fluorobenzyloksy)benzyIoamino]propanoamidy o wysokim stopniu czystości do zastosowania jako leki i preparaty farmaceutyczne je zawierające
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
EP2150239A1 (en) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
NO2155663T3 (el) 2007-06-15 2018-04-28
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
WO2009054964A1 (en) * 2007-10-22 2009-04-30 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
KR101709498B1 (ko) 2007-12-11 2017-02-23 뉴론 파마슈티칼즈 에스. 피. 에이. 고순도의 ２­［４­（３­ 또는 ２­플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법
CA2707646C (en) * 2007-12-19 2016-09-13 Newron Pharmaceuticals S.P.A. Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
US20110027354A1 (en) * 2008-04-01 2011-02-03 Kim Hyoung-Chun Anti-parkinsonian compounds
WO2009147432A1 (en) * 2008-06-02 2009-12-10 Generics [Uk] Limited An improved process for the preparation of amines
WO2009147430A1 (en) 2008-06-02 2009-12-10 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
HUE037974T2 (hu) * 2008-06-06 2018-09-28 Pharma Two B Ltd Gyógyászati kompozíció Parkinson-kór kezelésére
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
CN102858330B (zh) 2010-04-27 2015-07-22 纽朗制药有限公司 用于制备拉非酰胺甲磺酸盐或其r-对映异构体的方法
EP2563347B1 (en) 2010-04-30 2016-10-12 Teikoku Pharma USA, Inc. Propynylaminoindan transdermal compositions
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
US10196341B2 (en) 2011-08-19 2019-02-05 The Trustees Of Princeton University C-halogen bond formation
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9913812B2 (en) 2011-11-09 2018-03-13 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
US9205061B2 (en) 2012-11-02 2015-12-08 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
JP2016523918A (ja) * 2013-06-27 2016-08-12 シーダーズ−サイナイ メディカル センター 神経変性状態の予防および治療のためのアドレナリン受容体拮抗薬
SG11201608608PA (en) * 2014-04-21 2016-11-29 Civitas Therapeutics Inc Rapid relief of motor fluctuations in parkinson's disease
JP6446131B2 (ja) 2014-10-02 2018-12-26 メガバイオウッド カンパニー，リミテッド α−アミノアミド誘導体化合物及びこれを含む薬学的組成物
AU2016313138A1 (en) * 2015-08-27 2018-03-15 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
JP2019510088A (ja) * 2016-03-17 2019-04-11 ザ ジョンズ ホプキンス ユニバーシティーＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ Ｐａｒｉｓのファルネシル化によってパーキンソン病を予防または治療する方法
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
EP3568082A4 (en) * 2017-01-14 2020-12-09 Neurrx, SPC METHOD OF USING HUMAN EXCREMENTS AND SECRETS FOR THE EARLY DETECTION OF PARKINSON'S DISEASE
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
US11234961B2 (en) * 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
EA202091127A1 (ru) 2017-11-02 2020-09-22 Замбон С.П.А. Фармацевтические композиции, включающие сафинамид
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
WO2021109880A1 (zh) * 2019-12-06 2021-06-10 上海医药集团股份有限公司 药物组合物、成套药盒及其应用
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
WO2022047298A1 (en) * 2020-08-31 2022-03-03 Purdue Pharma L.P. Compositions and methods for levodopa delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4970200A (en) 1988-03-01 1990-11-13 Schering Aktiengesellschaft Agent for treatment of Parkinson's disease
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ATE258067T1 (de) * 1995-05-26 2004-02-15 Pfizer Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
ES2326373T3 (es) 2009-10-08
US20130053368A1 (en) 2013-02-28
CN102274517A (zh) 2011-12-14
PL1613296T3 (pl) 2009-12-31
NL300752I2 (el) 2016-07-05
SI1613296T1 (sl) 2009-10-31
US9492410B2 (en) 2016-11-15
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
CY2015025I1 (el) 2016-04-13
PL2070526T3 (pl) 2014-08-29
PT1613296E (pt) 2009-07-30
KR20060010745A (ko) 2006-02-02
NZ542910A (en) 2007-10-26
TW200505423A (en) 2005-02-16
JP2006522800A (ja) 2006-10-05
JP2013067647A (ja) 2013-04-18
AU2004228782B2 (en) 2010-05-20
WO2004089353A8 (en) 2005-09-01
IL171331A (en) 2012-03-29
DK1613296T3 (da) 2009-10-05
ATE435012T1 (de) 2009-07-15
DK2070526T3 (da) 2014-03-24
FR15C0054I1 (fr) 2015-11-09
IL216403A0 (en) 2011-12-29
BRPI0409364A (pt) 2006-04-25
KR101129015B1 (ko) 2012-04-20
IL216403A (en) 2015-01-29
HUS1500043I1 (hu) 2018-11-28
PT2070526E (pt) 2014-03-31
EP2070526B1 (en) 2014-02-26
US8283380B2 (en) 2012-10-09
NO334316B1 (no) 2014-02-03
WO2004089353A3 (en) 2004-12-16
CY1115286T1 (el) 2017-01-04
DE602004021790D1 (de) 2009-08-13
KR20110070929A (ko) 2011-06-24
CN102274517B (zh) 2018-08-31
AU2004228782A1 (en) 2004-10-21
RU2005131422A (ru) 2006-04-27
CA2523188A1 (en) 2004-10-21
NO2015018I1 (no) 2015-08-03
EP2070526A1 (en) 2009-06-17
RU2342929C2 (ru) 2009-01-10
TWI340640B (en) 2011-04-21
US20150150833A1 (en) 2015-06-04
SI2070526T1 (sl) 2014-05-30
US8901176B2 (en) 2014-12-02
NO2015018I2 (no) 2015-07-23
EP1613296A2 (en) 2006-01-11
CA2523188C (en) 2012-09-25
ES2454272T3 (es) 2014-04-10
NO20054640D0 (no) 2005-10-10
EP1613296B1 (en) 2009-07-01
CN1771030A (zh) 2006-05-10
CY2015025I2 (el) 2016-04-13
CY1109295T1 (el) 2014-07-02
WO2004089353A2 (en) 2004-10-21
NO335537B1 (no) 2014-12-22
MXPA05010873A (es) 2006-03-21
NO20131417L (no) 2005-12-09
AR044007A1 (es) 2005-08-24
FR15C0054I2 (fr) 2018-01-26

Similar Documents

Publication Publication Date Title
LU92782I2 (fr) Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
FR2886851B1 (fr) Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
WO2005034998A3 (en) Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EP1676512A3 (en) Skin treatment articles and methods
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
EP1945628A4 (en) NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY, AND THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER DISEASE
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
EP2407171A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2002028999A3 (en) Gene expression profiles in granulocytic cells
ITRM20050446A1 (it) Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari.
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
EP2035412A4 (en) MUSCARINIC RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
IL195431A0 (en) Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
FR2886850B1 (fr) Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
BRPI0811538A2 (pt) Uso de ciclosporinas no tratamento de pacientes com lentes intraoculares.
FR2866340B1 (fr) Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
IL174303A0 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
PL378360A1 (pl) Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju